Physician profile
Anan Afaneh
NPI 1407167273
$1,678.35
in general payments reported to CMS, 2019-2025
13 companies · $206 in 2025
The $206 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $41.79 · 2021: $16.65 · 2022: $329 · 2023: $637 · 2024: $313 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,155.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $532.56 | 2022-2025 | |
| Abbvie INC. | $258.02 | 2022-2025 | Rinvoq |
| Novartis Pharmaceuticals Corporation | $236.29 | 2019-2025 | |
| Amgen INC. | $203.52 | 2019-2025 | Enbrel, Uplizna, Otezla |
| Janssen Biotech, INC. | $128.62 | 2020-2022 | |
| Glaxosmithkline, LLC. | $89.49 | 2022-2023 | Benlysta |
| Actelion Pharmaceuticals US, INC. | $87.71 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $35.49 | 2023 | Saphnelo |
| Genentech USA, INC. | $35.02 | 2023-2025 | Actemra |
| Horizon Therapeutics Plc | $20.64 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.50 | 2024 | Orencia |
| Ucb, INC. | $18.97 | 2023 | Cimzia |
| Antares Pharma, INC. | $12.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anan Afaneh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.